Downregulation of MiR-505 Promotes Cell Proliferation, Migration and Invasion, and Predicts Poor Prognosis in Breast Cancer

Overview

Journal Oncol Lett

Specialty Oncology

Date 2019 Jul 11

PMID 31289494

Citations 9

Authors

Jian Wang

Haibo Liu

Minghong Li

Affiliations

Soon will be listed here.

Abstract

microRNAs are involved in the tumor progression of various cancer types. The present study aimed to determine the prognostic significance of microRNA-505 (miR-505) in patients with breast cancer and investigate the functional role of miR-505 in BCa progression. The expression of miR-505 was estimated using reverse transcription-quantitative polymerase chain reaction. Kaplan-Meier survival curves and Cox regression analysis were used to evaluate the prognostic value of miR-505 in patients with BCa. Cell experiments were performed to assess the biological function of miR-505 during BCa progression. A significant downregulated expression level of miR-505 was observed in BCa tissues and cells compared with the corresponding controls (P<0.001). The expression of miR-505 was significantly associated with distant metastasis status (P=0.013) and Tumor-Node-Metastasis staging (P=0.002). Furthermore, the overall survival time was significantly shorter for patients with low miR-505 expression compared with those with high miR-505 expression (P<0.001). In addition, miR-505 was identified as an independent prognostic factor for BCa. The results of cell experiments revealed that an overexpression of miR-505 could significantly inhibit BCa cell proliferation, migration and invasion, whereas a downregulation of miR-505 significantly enhanced BCa cell proliferation, migration and invasion (P<0.05). In summary, all data indicated that a low miR-505 expression level is associated with a poor prognosis for patients with BCa and promotes tumor cell proliferation, migration and invasion. Therefore, the aberrant expression of miR-505 may serve as a therapeutic target for BCa.

Citing Articles

RCE-IFE: recursive cluster elimination with intra-cluster feature elimination.

Kuzudisli C, Bakir-Gungor B, Qaqish B, Yousef M PeerJ Comput Sci. 2025; 11:e2528.

PMID: 40062294 PMC: 11888879. DOI: 10.7717/peerj-cs.2528.

Associations of plasma extracellular microRNAs with new-onset breast cancer in the Framingham heart study.

Karlin H, Larson M, Rong J, Huan T, Courchesne P, Freedman J Am J Cancer Res. 2024; 14(11):5568-5572.

PMID: 39659926 PMC: 11626277. DOI: 10.62347/KMFI7371.

A Novel TCGA-Validated, MiRNA-Based Signature for Prediction of Breast Cancer Prognosis and Survival.

Tian B, Hou M, Zhou K, Qiu X, Du Y, Gu Y Front Cell Dev Biol. 2021; 9:717462.

PMID: 34589485 PMC: 8473752. DOI: 10.3389/fcell.2021.717462.

Circular RNA promotes development of glioblastoma by regulating the miR-361-3p/miR-324-5p/ signaling pathway.

Li D, Li L, Chen X, Yang W, Cao Y Mol Ther Oncolytics. 2021; 22:483-494.

PMID: 34553034 PMC: 8433060. DOI: 10.1016/j.omto.2021.07.010.

lncRNA KTN1‑AS1 promotes glioma cell proliferation and invasion by negatively regulating miR‑505‑3p.

Mu Y, Tang Q, Feng H, Zhu L, Wang Y Oncol Rep. 2020; 44(6):2645-2655.

PMID: 33125151 PMC: 7640367. DOI: 10.3892/or.2020.7821.

References

Livak K, Schmittgen T . Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2002; 25(4):402-8. DOI: 10.1006/meth.2001.1262. View

Singletary S, Allred C, Ashley P, Bassett L, Berry D, Bland K . Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003; 83(4):803-19. DOI: 10.1016/S0039-6109(03)00034-3. View

Reis-Filho J, Lakhani S . The diagnosis and management of pre-invasive breast disease: genetic alterations in pre-invasive lesions. Breast Cancer Res. 2003; 5(6):313-9. PMC: 314410. DOI: 10.1186/bcr650. View

Pillai R, Bhattacharyya S, Artus C, Zoller T, Cougot N, Basyuk E . Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science. 2005; 309(5740):1573-6. DOI: 10.1126/science.1115079. View

Brenton J, Carey L, Ahmed A, Caldas C . Molecular classification and molecular forecasting of breast cancer: ready for clinical application?. J Clin Oncol. 2005; 23(29):7350-60. DOI: 10.1200/JCO.2005.03.3845. View

Shi M, Guo N . MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer. Cancer Treat Rev. 2009; 35(4):328-34. DOI: 10.1016/j.ctrv.2008.12.002. View

Blank P, Schwenkglenks M, Moch H, Szucs T . Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Res Treat. 2010; 124(2):497-507. DOI: 10.1007/s10549-010-0862-7. View

Bombonati A, Sgroi D . The molecular pathology of breast cancer progression. J Pathol. 2010; 223(2):307-17. PMC: 3069504. DOI: 10.1002/path.2808. View

Turchinovich A, Weiz L, Burwinkel B . Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci. 2012; 37(11):460-5. DOI: 10.1016/j.tibs.2012.08.003. View

10.

Xiong G, Deng L, Zhu J, Rychahou P, Xu R . Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition. BMC Cancer. 2014; 14:1. PMC: 3880410. DOI: 10.1186/1471-2407-14-1. View

11.

Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K . Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res. 2014; 34(3):1071-7. View

12.

Lei F, Zhang L, Li X, Lin X, Wu S, Li F . Overexpression of prostate tumor overexpressed 1 correlates with tumor progression and predicts poor prognosis in breast cancer. BMC Cancer. 2014; 14:457. PMC: 4070404. DOI: 10.1186/1471-2407-14-457. View

13.

Li W, Jin X, Zhang Q, Zhang G, Deng X, Ma L . Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. Int J Clin Exp Pathol. 2014; 7(6):3287-92. PMC: 4097245. View

14.

Yang H, Yu J, Wang L, Ding D, Zhang L, Chu C . miR-320a is an independent prognostic biomarker for invasive breast cancer. Oncol Lett. 2014; 8(3):1043-1050. PMC: 4114662. DOI: 10.3892/ol.2014.2298. View

15.

Lin F, Yao L, Xiao J, Liu D, Ni Z . MiR-206 functions as a tumor suppressor and directly targets K-Ras in human oral squamous cell carcinoma. Onco Targets Ther. 2014; 7:1583-91. PMC: 4166217. DOI: 10.2147/OTT.S67624. View

16.

Yu H, Li H, Qian H, Jiao X, Zhu X, Jiang X . Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer. Med Oncol. 2014; 31(11):283. DOI: 10.1007/s12032-014-0283-2. View

17.

Sun E, Zhou Q, Liu K, Wei W, Wang C, Liu X . Screening miRNAs related to different subtypes of breast cancer with miRNAs microarray. Eur Rev Med Pharmacol Sci. 2014; 18(19):2783-8. View

18.

Schmitz K, DiSipio T, Gordon L, Hayes S . Adverse breast cancer treatment effects: the economic case for making rehabilitative programs standard of care. Support Care Cancer. 2014; 23(6):1807-17. DOI: 10.1007/s00520-014-2539-y. View

19.

Zheng K, Liu W, Liu Y, Jiang C, Qian Q . MicroRNA-133a suppresses colorectal cancer cell invasion by targeting Fascin1. Oncol Lett. 2015; 9(2):869-874. PMC: 4301513. DOI: 10.3892/ol.2014.2753. View

20.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View